Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.43 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12224197 | 0.88 | L3MBTL1 (0.48) | DPP4DPP7DPP8DPP9CHRNB2 | |
| SCHEMBL10611575 | 0.87 | DPP4 (0.47) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL24102652 | 0.85 | L3MBTL1 (0.58) | DPP4DPP7DPP8DPP9L3MBTL1 | |
| SCHEMBL8264016 | 0.83 | — | — | |
| SCHEMBL10722676 | 0.80 | DPP4 (0.44) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL10611650 | 0.78 | DPP4 (0.44) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL10611656 | 0.77 | DPP4 (0.42) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL5050092 | 0.77 | DPP4 (0.39) | DPP4DPP7DPP8DPP9 | |
| SCHEMBL20221172 | 0.76 | L3MBTL1 (0.60) | L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL10663507 | 0.75 | L3MBTL1 (0.58) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149683-A1 | SUBSTITUTED AMINOPIPERIDINES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES | DPP4, DPP3, DPP7 | DPP4 1/4885DPP7 3/4885DPP8 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.